牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-01-08 AccNo: 0001213900-18-000220 Size: 33 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-01-03 AccNo: 0001213900-18-000058 Size: 99 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-12-28 AccNo: 0001213900-17-013700 Size: 16 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-12-21 AccNo: 0001213900-17-013532 Size: 10 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-12-18 AccNo: 0001213900-17-013333 Size: 27 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-11-27 AccNo: 0001213900-17-012584 Size: 133 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-11-27 AccNo: 0001213900-17-012582 Size: 30 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2017-11-21 AccNo: 0001213900-17-012446 Size: 49 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-11-17 AccNo: 0001213900-17-012265 Size: 24 KB 网页链接
$Can-Fite Biopharma Ltd Sponsored ADR (Israel)(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-11-15 AccNo: 0001213900-17-012136 Size: 173 KB 网页链接